Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial-Reference-Cited by-同舟云学术

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial

Published:2011-09 Issue:9 Volume:12 Page:841-851
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Kantarjian Hagop M,Hochhaus Andreas,Saglio Giuseppe,De Souza Carmino,Flinn Ian W,Stenke Leif,Goh Yeow-Tee,Rosti Gianantonio,Nakamae Hirohisa,Gallagher Neil J,Hoenekopp Albert,Blakesley Rick E,Larson Richard A,Hughes Timothy P

Publisher

Elsevier BV

Subject

Oncology

Reference26 articles.

1. Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib;Manley;Bioorg Med Chem,2010

2. Tasigna (nilotinib) [package insert];Novartis,2010

3. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia;Saglio;N Engl J Med,2010

4. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR–ABL transcripts and kinase domain mutations and for expressing results;Hughes;Blood,2006

5. Desirable performance characteristics for BCR–ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials;Branford;Blood,2008

Cited by 431 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring;American Journal of Hematology;2024-08-02

2. Therapeutic options for chronic myeloid leukemia following the failure of second-generation tyrosine kinase inhibitor therapy;Frontiers in Oncology;2024-07-29

3. What clinicians should know about surrogate end points in hematologic malignancies;Blood;2024-07-04

4. Evaluation of the gene fusion landscape in early onset sporadic rectal cancer reveals association with chromatin architecture and genome stability;Oncogene;2024-06-27

5. Development and validation of a nomogram to predict poor efficacy of imatinib in the treatment of newly diagnosed chronic phase chronic myeloid leukemia patients;Frontiers in Oncology;2024-06-24